NCT01490749View on ClinicalTrials.gov

Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Esophageal CancerNeoplasms, Esophageal
Interventions
DRUG

RAD001

Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.

DRUG

XELOX

Patients will receive two cycles of XELOX.

DRUG

Carboplatin

Given on a 3 weeks on and 1 week off schedule.

RADIATION

Radiation

1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.

Trial Locations (3)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Winship Cancer Institute, Atlanta

37232

Vanderbilt University, Nashville

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Emory University

OTHER

NCT01490749 - Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | Biotech Hunter | Biotech Hunter